Neuprotection of post-acute COVID-19 cognitive impairment

Close metadata

OBJECTIVE

To evaluate the efficacy of Cortexin in the treatment of patients with post-Covid impairment.

MATERIAL AND METHODS

Treatment results of 109 patients with post-Covid cognitive impairment aged from 42 to 65 years were analyzed. The main group (MG, n=52), 29 (55.8%) men and 23 (44.2%) women, average age 58.1±4.9 years, who received Cortexin continuously for 20 days at a dose of 10 mg i.m., after 3, 6 months. The comparison group included 57 people, 31 (54.4%) men and 26 (45.6%) women (average age 59.3±3.8 years). The effectiveness of therapy was assessed using neuropsychological testing with international scales.

RESULTS

During treatment, statistically significant differences were obtained in MG patients in the form of improved concentration (p<0.05), increased control of exutative functions (p<0.05), and auditory-verbal memory (p=0.002). There were no adverse events in the MG.

CONCLUSION

Cortexin is highly effective and safe, and can be recommended as part of a combined staged therapy for post-Covid cognitive impairment. Thus, the study confirms the feasibility of using Cortexin, which has a neurocytoprotective effect.

Keywords:

coronavirus SARS-CoV2

post-COVID syndrome

post-COVID cognitive impairment

neurophysiological parameters

Cortexin

Authors:

Melnik E.A.

Omsk State Medical University;
Regional Clinical Hospital

ORCID: 0009-0005-1526-2884

Received:

19.04.2024

Accepted:

22.04.2024

List of references:

Woo MS, Malsy J, Puttgen J, et al.Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020;2(2):fcaa205. https://doi.org/10.1093/braincomms/fcaa205
Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020;129:98-102. https://doi.org/10.1016/j.jpsychires.2020.06.022
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. https://doi.org/10.1038/s41591-021-01283-z
Editorial. Long COVID: Let patients help define long-lasting COVID symptoms. Nature. 2020;586:170. https://doi.org/10.1038/d41586-020-02796-2
Nabavi N. Long COVID: How to define it and how to manage it. BMJ. 2020:370.m3489. https://doi.org/10.1136/bmj.m3489
Khasanova DR, Zhitkova YuV, Vaskaeva GR. Post-COVID syndrome: a review of pathophysiology, neuropsychiatric manifestations and treatment perspectives. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):93-98. (In Russ.). https://doi.org/10.14412/2074-2711-2021-3-93-98
National Institute for Health and Care Excellence, 2020. COVID-19 rapid guideline: Managing the long-term effects of COVID-19. NICE guideline [NG188]. Published date: 18 December 2020. Accessed June 12, 2023. Available at: www.nice.org.uk/guidance/ng188
Nabavi N. Long COVID: How to define it and how to manage it. BMJ. 2020:370.m3489. https://doi.org/10.1136/bmj.m3489
Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study. medRxiv. 2020;10.20.20215863. https://doi.org/10.1101/2020.10.20.20215863
Mcloughlin BC, Miles A, Webb TE, et al.Functional and cognitive outcomes after COVID-19 delirium. Eur Geriatr Med. 2020;11(5):857-862. https://doi.org/10.1007/s41999-020-00353-8
Frontera JA, Lewis A, Melmed K, et al. Prevalence and Predictors of Prolonged Cognitive and Psychological Symptoms Following COVID-19 in the United States. Front Aging Neurosci. 2021;13:690383. https://doi.org/10.3389/fnagi.2021.690383
Alemanno F, Houdayer E, Parma A, et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: ACOVIDrehabilitation unit experience. PLoS One. 2021;16:e0246590. https://doi.org/10.1371/journal.pone.0246590
Putilina MV, Teplova NV, Gerasimova OS. Differentiated approach to treatment of cognitive disorders associated with SARS-CoV-2 (COVID-19), taking into account comorbidity factor. Medical Alphabet. 2021;(22):18-24. (In Russ.).
Maltezou HC, Raftopoulos V, Vorou R, et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis. 2021;223(7):1132-8. https://doi.org/10.1093/infdis/jiaa804
Pilotto A, Cristillo V, Cotti Piccinelli S, et al. COVID-19 severity impacts on long-term neurological manifestation after hospitalisation. medRxiv preprint. https://doi.org/10.1101/2020.12.27.20248903
Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and healthrelated quality of life after hospitalization for COVID-19. J Infect J. 2020:19-22. https://doi.org/10.1016/j.jinf.2020.08.029
huang c, huang l, wang y. et al. 6-month consequences of covid-19 in patients discharged from hospital: a cohort study. lancet. 2021;397:220-232. https://doi.org/10.1016/s0140-6736(20)32656-8
Agosta F, Barbieri A, Bernasconi P, et al. Cognitive and behaviorial features of a cohort of patients in COVID-19 post-acute phase. Eur J Neurol. 2021;28(1):207-334. https://doi.org/10.1111/ene.14974
Miskowiak K, Johnsen S, Sattler S, et al. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39-48. https://doi.org/10.1016/j.euroneuro.2021.03.019
Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol. 2020;92(6):612-617. https://doi.org/10.1002/jmv.25735
Ostroumova OD, Ebzeeva EYu, Polyakova OA. Therapy of asthenia in patients after acute novel coronavirus infection (COVID-19): results of a multicenter, randomized, double-blind, placebocontrolled clinical study. Therapy. 2022;8(8):146-157. https://doi.org/10.18565/therapy.2022.8.146-157
Zheng Z, Peng F, Xu B, et al. Risk Factors of Critical &Mortal COVID-19 Cases: A Systematic Literature Review and Meta-analysis. J Infect. 2020;34(7):34-39. https://doi.org/10.1016/j.jinf.2020.04.021
Watson C, Thomas R, Solomon T, et al. COVID-19 and psychosis risk: Real or delusional concern? Neurosci Lett. 2021;741:135491. https://doi.org/10.1016/j.neulet.2020.135491
Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARSCoV-2: From neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol. 2021;267;(8):2179-2184. https://doi.org/10.1007/s00415-020-09929-7
Kurushina OV, Barulin AE. Damage to the central nervous system in COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(1):92-97. (In Russ.). https://doi.org/10.17116/jnevro202112101192
Cheremin RA, Skipetrova LA, Chugunov AV. Neurological Signs of Postcovid Syndrome. Neurosci Behav Physiol. 2022;52(7):968-994. https://doi.org/10.1007/s11055-022-01324-1
Baig A, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution. Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosc. 2020;11(7):995-998. https://doi.org/10.1021/acschemneuro.0c00122
Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24:168-175. https://doi.org/10.1038/s41593-020-00758-5
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate andlong-term consequences of COVID-19 infections for the development ofneurological disease. Alzheimers Res Ther. 2020;12(1):69. https://doi.org/10.1186/s13195-020-00640-3
Gomazkov OA. Cortexin. Molecular mechanisms and targets of neuroprotective activity. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(8):99-104. (In Russ.). https://doi.org/10.17116/jnevro20151158199-104
Wostyn P. COVID-19 and chronic fatigue syndrome: is the worst yet to come? Med Hypotheses. 2021;146(75):110469. https://doi.org/10.1016/j.mehy.2020.110469
Rudroff T, Fietsam A, Deters J, et al. Post-COVID-19 Fatigue: Potential Contributing Factors. Brain Sci. 2020;10(12):1012. https://doi.org/10.3390/brainsci10121012
Miners S, Kehoe P, Love S. Cognitive impact of COVID-19: looking beyond the shortterm. Alzheimers Res Ther. 2020;12:170-176. https://doi.org/10.1186/s13195-020-00744-w
Alexeeva NT, Sokolov DA, Nikityuk DB, et al. Molecular and cellular mechanisms of central nervous system alteration in COVID-19. Journal of Anatomy and Histopathology. 2020;9(3):72-85. (In Russ.). https://doi.org/10.18499/2225-7357-2020-9-3-72-85
Recommendations for the management of patients with coronavirus infection COVID-19 in the acute phase and post-Covid syndrome in an outpatient setting. Ed. prof. Vorobyova P.A. Problems of Standardization In Healthcare. 2021;7-8:3-96. (In Russ.). https://doi.org/10.26347/1607-2502202107-08003-096
Abassi Z, Knaney Y, Karram T, Heyman S. The lung macrophagein SARS-CoV-2 infection: a friend or a foe? Front Immunol. 2020;5(11):1312. https://doi.org/10.3389/fimmu.2020.01312
Varga Z, Flammer A, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418. https://doi.org/10.1016/s0140-6736(20)30937-5
Varatharaj A, Thomas N, Ellul M, et al. Neurological and neuropsychiatric complicationsof COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7:875-882. https://doi.org/10.1016/s2215-0366(20)30287-x
Siow I, Lee K, Zhang J, et al. Stroke as a neurological complication of COVID-19:A systematic review and meta-analysis of incidence, outcomes and predictors. J Stroke Cerebrovasc Dis. 2021;30 (3):105549. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105549
Poyiadji N, Shahin G, Noujaim D, et al. COVID19associatedacute hemorrhagic necrotizingencephalopathy: CT and MRI features. Radiology. 2020;23(7):34-39. https://doi.org/10.1148/radiol.2020201187
Kreye J, Reincke S, Prüss H. Do cross-reactive antibodies cause neuropathology in COVID-19? Nat Rev Immunol. 2020;20(11):645-646. https://doi.org/10.1038/s41577-020-00458-y
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629. https://doi.org/10.1172/jci137244
Alexandrova NA, Evzelman MA. Reusable coursework in treatment post-stroke cognitive impairment. The book Cerebrovascular pathology. New possibilities of low-dose neuroprotective. Ed. A.A. Skoromets, L.V. Stakhovskaya. St. Petersburg: Science; 2014;72-81. (In Russ.).
Aliferova VM, Dadasheva MN, Doronin BM, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(4):41-46. (In Russ.).
Kovalenko AV Safronova MN, Mizyurkina OA. influencecortexin restoration of speech function ischemic stroke. The book Cerebrovascular pathology. New possibilities of low-doseneuroprotective. Ed. A.A. Skoromets, L.V. Stakhovskaya. St. Petersburg: Science; 2014; 82-88. (In Russ.).
Melnik EA. Neuroprotection acute and chronic cerebrovascular insufficiency. by editors Skorometz A.A., Dykonov M. M. Neuroprotection acute and chronic cerebrovascular insufficiency St. Petersburg: Science; 2007;48-66. (In Russ.).
Pinelis VG, Storozhevykh TP, Surin AM, et al. Neuroprotective effects of cortagen, cortexin and semax on glutamate neurotoxicity». 30th European Peptide Symposium (30EPS), Helsinki, 30 August — 5 September 2008. J Mod Phys. 2013;4(1):23-25.
Skoromets AA, Stakhovskaya LV, Belkin AA, et al. New opportunities neuroprotective in treatment ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2008;108(7):32-38. (In Russ.).
Skoromets AA, Dykonov MM. I. I. Pavlov, brain and cortexin The Bulletin Emergency Medicine. 2010;1:95-96. (In Russ.).

Close metadata